The hypoxia marker CA-IX is prognostic in soft tissue sarcoma patients treated in the UK phase III VORTEX trial. (July 2016) - Forker, L.; Sioletic, S.; Shenjere, P.; Irlam, J.; Valentine, H.; Hughes, D.; Hughes, A.; Gaunt, P.; Robinson, M.; West, C.